Novartis: Arthritis, Juvenile trials

The registry lists 18 Arthritis, Juvenile studies with Novartis as lead sponsor. 6 are open to participants now and 8 have results posted.

Phase 1 2Phase 2 2Phase 3 9No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease PatientsRecruitingNCT07517250
• Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in KoreaRecruitingNCT07243782
• A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's DiseaseRecruitingNCT07203001Phase 2
• Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry.Not yet recruitingNCT07190053
• Ilaris NIS in KoreaRecruitingNCT06838143
• Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).RecruitingNCT06751238Phase 1
• An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)CompletedNCT03769168Phase 3Results posted
• Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)CompletedNCT03031782Phase 3Results posted
• Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIACompletedNCT02396212Phase 3Results posted
• A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 StudiesCompletedNCT02334748Phase 3Results posted
• ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of CanakinumabCompletedNCT02296424Phase 3Results posted
• An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.CompletedNCT00891046Phase 3Results posted
• Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)CompletedNCT00889863Phase 3Results posted
• Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)TerminatedNCT00886769Phase 3Results posted
• Managed Access Programs for MAS825, ArumakimigTemporarily not availableNCT07889310
• Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic ArthritisWithdrawnNCT06431750
• An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)WithdrawnNCT01676948Phase 3
• Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)CompletedNCT00426218Phase 1/2